62a2cbf8-51be-469b-978c-bdf386e0d651
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 90
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- CHOLESTEROL_HOMEOSTASIS+0.330
- APICAL_JUNCTION+0.270
- P53_PATHWAY+0.270
- WNT_BETA_CATENIN_SIGNALING+0.250
- MYOGENESIS+0.240
- APICAL_SURFACE+0.220
- NOTCH_SIGNALING+0.220
- XENOBIOTIC_METABOLISM+0.200
- KRAS_SIGNALING_DN+0.190
- HYPOXIA+0.160
Top 10 suppressed
- E2F_TARGETS-0.480
- MYC_TARGETS_V1-0.480
- PROTEIN_SECRETION-0.430
- G2M_CHECKPOINT-0.420
- MTORC1_SIGNALING-0.280
- ANDROGEN_RESPONSE-0.270
- ANGIOGENESIS-0.260
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.260
- UNFOLDED_PROTEIN_RESPONSE-0.260
- UV_RESPONSE_DN-0.260
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MDT-AP-1336 | Med | Medulloblastoma | 0.818 |
| 2 | BS_X0F9AYEC | pilocytic astrocytoma | — | 0.799 |
| 3 | R147 | — | — | 0.791 |
| 4 | 8f518c0d-42e0-4418-bb48-f69b32446b46 | — | — | 0.789 |
| 5 | 1e82995c-f318-4225-96d4-f1e98bcbf60b | — | — | 0.773 |
| 6 | 299f36bd-d9fd-41f5-8a29-3382e147a14f | — | — | 0.770 |
| 7 | SAMN03290915 | — | — | 0.766 |
| 8 | 433318f9-74f1-4d4a-b94c-5825993747d4 | — | — | 0.756 |
| 9 | MNG559 | — | — | 0.755 |
| 10 | SRR23303751 | — | — | 0.752 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 26 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| CHOLESTEROL_HOMEOSTASIS | 0.330 | Remibrutinib | — uncovered |
| APICAL_JUNCTION | 0.270 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.270 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.250 | Inavolisib | — uncovered |
| MYOGENESIS | 0.240 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.220 | Temsirolimus | — uncovered |
| NOTCH_SIGNALING | 0.220 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.200 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.190 | Remibrutinib | — uncovered |
| HYPOXIA | 0.160 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.150 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.150 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.150 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.130 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.110 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.110 | Remibrutinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.100 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.090 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.070 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.070 | Inavolisib | — uncovered |